INTRACELLULAR SIGNALLING PATHWAYS IN DIABETIC NEPHROPATHY: NEW TARGETS FOR NEPHROPROTECTION


Дәйексөз келтіру

Толық мәтін

Аннотация

New approaches to nephroprotection in diabetic nephropathy, based on pharmacological protein-kinase C inhibition, blockade of signaling patheays (Smad, Janus-kinase/stat) as well as with PPAR-agonists are discussed

Авторлар туралы

I Bondar'

V Klimontov

Әдебиет тізімі

  1. Schernthaner G. Kidney disease in diabetology: lessons from 2007. Nephrol. Dial. Transplant. 2008; 22 (3): 1112-1115.
  2. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48 (8): 1439-1444.
  3. van Dijk P.C.W., Jager K.J., Stengel B. et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registeries in Europe (1991-2000). Kidney Int. 2005; 67: 1489-1499.
  4. The diabetic kidney. Ed. P. Cortes, C.E. Mogensen. Totowa, New Jersey: Humana Press, 2006.
  5. Kanwar Y.S., Wada J., Sun L. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood). 2008; 233 (1): 4-11.
  6. Qi W., Chen X., Poronnik P., Pollock C.A. Transforming growth factor-beta/connective tissue growth factor axis in the kidney. Int. J. Biochem. Cell. Biol. 2008; 40 (1): 9-13.
  7. Mitu G., Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Front. Biosci. 2008; 13: 4726-4739.
  8. Hayashida T., Schnaper H.W. High ambient glucose enhances sensitivity to TGF-beta1 via extracellular signal-regulated kinase and protein kinase C delta activities in human mesangial cells. J. Am. Soc. Nephrol. 2004; 15 (8): 2032-2041.
  9. Langham R., Kelly D.J., Gow R.M. et al. Increased renal gene transcription of protein kinase C-beta in human diabetic nephropathy: relationship to long-tern glycaemic control. Diabetologia 2008; 51 (4): 668-674.
  10. Meier M., Menne J., Haller H. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. Diabetologia 2009; 52 (5): 765-775.
  11. Menne J., Park J.K., Boehne M. et al. Diminished loss of proteoglycans and lack of albuminuria in Rpotein Kinase C deficient diabetic mice. Diabetes 2004; 53 (8): 2101-2109.
  12. Meier M., Menne J., Park J.K. et al. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of α-protein kinase C signalling in vivo. Kidney Int. 2006; 70 (8): 1456-1462.
  13. Ohshiro Y., Ma R.C., Yasuda Y. et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice. Diabetes 2006; 55 (11): 3112-3120.
  14. Meier M., Park J.K., Overheu D. et al. Deletion of protein kinase C-β isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced dibetes mouse model. Diabetes 2007; 56 (2): 346-354.
  15. Meier M., Menne J., Park J.K. et al. Deletion of protein kinase C-ε signalling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J. Am. Soc. Nephrol. 2007; 18 (4): 1190-1198.
  16. Berrou J., Tostivint I., Verrecchia F. et al. Advanced glycation end products regulate extracellular matrix protein and protease expression by human glomerular mesangial cells. Int. J. Mol. Med. 2009; 23 (4): 513-520.
  17. Li J.H., Wang W., Huang X.R. et al Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 2004; 164 (4): 1389-1397.
  18. Fukami K., Ueda S., Yamagishi S. et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004; 66 (6): 2137-2147.
  19. Chung A.C., Zhang H., Kong Y.Z. et al Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J. Am. Soc. Nephrol. 2010; 21 (2): 249-260.
  20. Mason R.M. Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J. Cell. Commun. Signal. 2009; 3 (2): 95-104.
  21. Wang S., Hircshberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor β in mesangial cells. J. Biol. Chem. 2004 (22); 279: 23200-23206.
  22. Fugimoto M., Maezawa Y., Yokote K. et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biochys. Res. Commun. 2003; 305: 1002-1007.
  23. Wang A., Ziyadeh F.N., Lee E.Y. et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am. J. Physiol. Renal. Physiol. 2007; 293 (5): F1657-F1665.
  24. Hohenstein B., Daniel C., Hausknecht B. et al. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol. Dial. Transplant. 2008; 23 (12): 3880-3887.
  25. Boucherot A.H.A., Cohen C.D., Schin M.L. et al. Jak/Stat activation in diabetic nephropathy in humans but not mice: transcriptional analysis. J. Am. Soc. Nephrol. 2006; 17: 60A.
  26. Wang X., Shaw S., Amiri F. et al. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 2002; 51 (12): 3505-3509.
  27. Amiri F., Shaw S., Wang X. et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int. 2002; 61 (5): 1605-1616.
  28. Lieberthal W., Levine J.S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 2009; 20 (12): 2493-2502.
  29. Nagai K., Matsubara T., Mima A. et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 2005; 68 (2): 552-561.
  30. Sakaguchi M., Isono M., Isshiki K. et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem. Biophys. Res. Commun. 2006; 340 (1): 296-301.
  31. Lee M.J., Feliers D., Mariappan M.M. et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am. J. Physiol. Renal. Physiol. 2007; 292 (2): F617-F627.
  32. Sataranatarajan K., Mariappan M.M., Lee M.J. et al. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am. J. Pathol. 2007; 171 (6): 1733-1742.
  33. Kume S., Uzu T., Isshiki K., Koya D. Peroxisome proliferator-activated receptors in diabetic nephropathy. PPAR Res. 2008; 879523.
  34. Park C. W., Kim H. W., Ko S. H. et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor-α. Diabetes 2006; 55 (4): 885-893.
  35. Isshiki K., Haneda M., Koya D. et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49 (6): 1022-1032.
  36. Zheng F., Fornoni A., Elliot S. J. et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am. J. Physiol. Renal Physiol. 2002; 282 (4): F639-F648.
  37. Panchapakesan U., Sumual S., Pollock C.A. et al. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. J. Physiol. Renal. Physiol. 2005; 289 (5): F1153-F1158.
  38. Zafiriou S., Stanners S. R., Saad S. et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J. Am. Soc. Nephrol. 2005; 16 (3): 638-645.
  39. Ohga S., Shikata K., Yozai K. et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal. Physiol. 2007; 292 (4): F1141-F1150.
  40. Ko G.J., Kang Y.S., Han S.Y. et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. 2008; 23 (9): 2750-2760.
  41. Kelly D.J., Zhang Y., Hepper C. et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52 (2): 512-518.
  42. Kelly D.J., Buck D., Cox A.J. et al. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 2007; 293 (2): F565-F574.
  43. Tuttle K.R., Bakris G.L., Toto R.D. et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28 (11): 2686-2690.
  44. Gilbert R.E., Kim S.A., Tuttle K.R. et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 2007; 30 (4): 995-996.
  45. Tuttle K.R., McGill J.B., Haney D.J. et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin. J. Am. Soc. Nephrol. 2007; 2 (4): 631-636.
  46. Kobayashi T., Inoue T., Okada H. et al. Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin. Exp. Nephrol. 2005; 9 (2): 114-121.
  47. Petersen M., Thorikay M., Deckers M. et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 2008; 73 (6): 705-715.
  48. Li J., Kang S.W., Kim J.L. et al. Isoliquiritigenin entails blockade of TGF-beta1-SMAD signaling for retarding high glucose-induced mesangial matrix accumulation. J. Agric. Food Chem. 2010; 58 (5): 3205-3212.
  49. Okazaki Y., Yamasaki Y., Uchida H.A. et al. Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor. Clin. Exp. Nephrol. 2007; 11 (1): 77-87.
  50. Mulay S.R., Gaikwad A.B., Tikoo K. Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin-induced type I diabetic nephropathy. Chem. Biol. Interact. 2010; 185 (2): 137-142.
  51. Marrero M.B., Banes-Berceli A.K., Stern D.M., Eaton D.C. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 2006; 290 (4): F762-F768.
  52. Ortiz-Muñoz G., Lopez-Parra V., Lopez-Franco O. et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 21 (5): 763-772.
  53. Shi Y., Du C., Zhang Y. et al. Suppressor of сytokine signaling-1 ameliorates expression of MCP-1 in diabetic nephropathy. Am. J. Nephrol. 2010; 31 (5): 380-388.
  54. Banes-Berceli A.K., Shaw S., Ma G. et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am. J. Physiol. Renal. Physiol. 2006; 291 (1): F116-F121.
  55. Shi Y.H., Zhao S., Wang C. et al. Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharmacol. Sin. 2007; 28 (12): 1938-1946.
  56. Wittmann S., Daniel C., Stief A. et al. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 2009; 87 (9): 1290-1299.
  57. Senior P.A., Zeman M., Paty B.W. et al. Changes in renal function after clinical islet transplantation: four-year observational study. Am. J. Transplant. 2007; 7 (1): 91-98.
  58. Maffi P., Bertuzzi F., De Taddeo F. et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007; 30 (5): 1150-1155.
  59. Park C.W., Zhang Y., Zhang X. et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006; 69 (9): 1511-1517.
  60. Keech A., Simes R.J., Barter P. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366 (9500): 1849-1861.
  61. Kamijo Y., Hora K., Kono K. et al. PPARα protects proximal tubular cells from acute fatty acid toxicity. J. Am. Soc. Nephrol. 2007; 18 (12): 3089-3100.
  62. Hanefeld M., Brunetti P., Schernthaner G.H. et al. One-year glycemic control with a suifonyurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27 (1): 141-147.
  63. Schernthaner G., Matthews D.R., Charbonnel B. et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab. 2004; 89 (12): 6068-6076.
  64. Matthews D.R., Charbonnel B.H., Hanefeld M. et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diab. Metab. Res. Rev. 2005; 21 (2): 167-174.
  65. Bakris G.L., Ruilope L.M., McMorn S.O. et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J. Hypertens. 2006; 24 (10): 2047-2055.
  66. Sarafidis P.A., Stafylas P.C., Georgianos P.I. et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am. J. Kidney Dis. 2010; 55 (5): 835-847.
  67. Okada T., Wada J., Hida K. et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 2006; 55 (6): 1666-1677.
  68. Nakamura T., Ushiyama C., Osada S. et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50 (10): 1193-1196.
  69. Kim M.K., Ko S.H., Baek K.H. et al. Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J. Intern. Med. 2009; 24 (3): 227-232.
  70. Cha D.R., Zhang X., Zhang Y. et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007; 56 (8): 2036-2045.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>